Literature DB >> 1416897

In vitro susceptibility of Mycobacterium kansasii to clarithromycin.

J Biehle1, S J Cavalieri.   

Abstract

The MICs of the macrolide clarithromycin for 31 clinical isolates of Mycobacterium kansasii were determined by three different methods. The methods employed were the proportion resistance method on 7H10 agar, the radiometric (BACTEC) method, and the T100 method of datum analysis. All methods gave similar results. The MICs were in a narrow range from 0.16 to 0.50 microgram/ml, with the MICs for 90% of isolates tested of 0.50 microgram/ml for the agar dilution and radiometric methods and 0.37 microgram/ml for the T100 method. The MBCs were determined for nine representative isolates by the radiometric broth method. The MBCs were equal to the MICs for four isolates, and the MBCs were twofold higher than the MICs for five isolates. Killing of 99.9% of the bacterial population was achieved at a clarithromycin concentration of 2.0 micrograms/ml for all nine isolates tested.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1416897      PMCID: PMC192433          DOI: 10.1128/AAC.36.9.2039

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Pulmonary and disseminated infection due to Mycobacterium kansasii: a decade of experience.

Authors:  M Lillo; S Orengo; P Cernoch; R L Harris
Journal:  Rev Infect Dis       Date:  1990 Sep-Oct

2.  Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin.

Authors:  W Pezzia; J W Raleigh; M C Bailey; E A Toth; J Silverblatt
Journal:  Rev Infect Dis       Date:  1981 Sep-Oct

3.  Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.

Authors:  D J Hardy; R N Swanson; R A Rode; K Marsh; N L Shipkowitz; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

4.  The activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae, determined by in-vitro and serum bactericidal tests.

Authors:  H Dabernat; C Delmas; M Seguy; J B Fourtillan; J Girault; M B Lareng
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

5.  In-vitro activity of clarithromycin combined with its 14-hydroxy metabolite A-62671 against Haemophilus influenzae.

Authors:  B Olsson-Liljequist; B M Hoffman
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

6.  Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms.

Authors:  B A Brown; R J Wallace; G O Onyi; V De Rosas; R J Wallace
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

7.  Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin.

Authors:  E A Gorzynski; S I Gutman; W Allen
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

8.  Mycobacterium kansasii infections in patients positive for human immunodeficiency virus.

Authors:  J L Carpenter; J M Parks
Journal:  Rev Infect Dis       Date:  1991 Sep-Oct

9.  Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex.

Authors:  C Truffot-Pernot; B Ji; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

10.  Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial.

Authors:  B Dautzenberg; C Truffot; S Legris; M C Meyohas; H C Berlie; A Mercat; S Chevret; J Grosset
Journal:  Am Rev Respir Dis       Date:  1991-09
View more
  4 in total

1.  Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages.

Authors:  N Mor; A Esfandiari
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

2.  Drug Susceptibility Profiling and Genetic Determinants of Drug Resistance in Mycobacterium kansasii.

Authors:  Zofia Bakuła; Magdalena Modrzejewska; Lian Pennings; Małgorzata Proboszcz; Aleksandra Safianowska; Jacek Bielecki; Jakko van Ingen; Tomasz Jagielski
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

3.  Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid.

Authors:  R S Witzig; S G Franzblau
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

4.  Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis.

Authors:  S J Cavalieri; J R Biehle; W E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.